Squibb Company (NYSE: BMY) and Pfizer
Inc. (NYSE: PFE) today announced the U.S. Food and Drug
Administration (FDA) has approved a Supplemental New Drug Application
(sNDA) for Eliquis for the treatment of DVT and PE, and for the
reduction in the risk of recurrent DVT and PE following initial therapy.
for U.S. FDA Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and for the Reduction in the Risk of Recurrent DVT and PE Following Initial Therapy investment picks